{"id":"W4410811541","doi":"10.1200/jco.2025.43.16_suppl.5056","title":"Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; BC Cancer Agency; Princess Margaret Cancer Centre; Dalhousie University; McGill University; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Université de Montréal; London Health Sciences Centre; McMaster University; University of Toronto; Western University; Juravinski Cancer Centre; University of British Columbia; University Health Network; Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Cancer; Internal medicine; Oncology; Biomarker; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002760206,0.001340463,0.0017248,0.0006105885,0.001322262,0.001059801,0.001368802,0.002165231,0.01426775],"category_scores_gemma":[0.002900979,0.0005709512,0.001456517,0.001495072,0.0006292861,0.0004591499,0.0005195047,0.001960052,0.002084708],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00450872,"about_ca_system_score_gemma":0.01070841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.07179886,"about_ca_topic_score_gemma":0.2673553,"domain_scores_codex":[0.9987444,0.0006250998,0.00006126279,0.0001188531,0.0002078534,0.0002424345],"domain_scores_gemma":[0.9981841,0.0002705898,0.0004045877,0.0001777125,0.0002582274,0.000704719],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5576819,0.005297673,0.01082236,0.004055693,0.002716303,0.0003305417,0.0002886811,0.00210777,0.01291428,0.00228138,0.3039024,0.09760119],"study_design_scores_gemma":[0.759606,0.03503792,0.06584128,0.0006479871,0.001839585,0.0003010287,0.00009633871,0.001156049,0.002249993,0.001188184,0.1319365,0.00009920535],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4580422,0.01448872,0.002509024,0.01356784,0.00262216,0.1435576,0.2648596,0.0008989574,0.09945393],"genre_scores_gemma":[0.6459047,0.009981685,0.01146444,0.02114999,0.002206904,0.1221628,0.1425363,0.0004528473,0.04414025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07179886,"threshold_uncertainty_score":0.1427619,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06804452329736803,"score_gpt":0.4216911073498777,"score_spread":0.3536465840525096,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}